Avicanna Introduces QUIXTM Rapid-Onset Medical Cannabis Portfolio

Initial Medical Cannabis SKUs, Including Rapid-Onset Capsules and Soft Chews, Planned for Q3 2026 Improving Patient Access with Accurately Dosed, Rapid-Onset and Non-Combustible Formats TORONTO, July 16, 2026 (GLOBE NEWSWIRE) — Avicanna Inc. (“Avicanna” or the “Company”) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN), a biopharmaceutical company focused on the development, manufacturing and commercialization of plant-derived [...]

Initial Medical Cannabis SKUs, Including Rapid-Onset Capsules and Soft Chews, Planned for Q3 2026 Improving Patient Access with Accurately Dosed, Rapid-Onset and Non-Combustible Formats TORONTO, July 16, 2026 (GLOBE NEWSWIRE) — Avicanna Inc. (“Avicanna” or the “Company”) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN), a biopharmaceutical company focused on the development, manufacturing and commercialization of plant-derived cannabinoid-based products, today announced the introduction of its proprietary QUIXTM-powered rapid-onset medical cannabis portfolio, with initial SKUs to be available across Canadian medical cannabis channels starting the third quarter of 2026 and additional SKUs planned for later in the year.

The new portfolio reflects the Company’s continued focus on supporting the evolution of medical cannabis through standardized, accurately dosed, and non-combustible product formats. The introduction represents an important milestone in Avicanna’s strategy to translate its scientific platform and proprietary drug delivery technologies into differentiated, evidence-based cannabinoid products. The initial SKUs are expected to become available nationwide through Canadian medical cannabis channels, including Avicanna’s MyMedi.ca medical cannabis care platform in August.

Commercializing Avicanna’s Proprietary QUIXTM Nanotechnology Platform QUIXTM is Avicanna’s proprietary, evidence-based, self-emulsifying drug delivery technology developed to address inherent challenges associated with cannabinoid delivery, including poor water solubility, low and variable bioavailability, and delayed onset of effects. The liquid technology produces nano-sized cannabinoid droplets designed to provide rapid onset, enhanced cannabinoid absorption and consistent product performance. The technology has also been optimized for long-term cannabinoid stability and improved sensory characteristics.

Leveraging years of research and development, and real-world experience, Avicanna has incorporated QUIXTM nanotechnology into a portfolio of over 20 proprietary SKUs, including nano drops, soft chews, capsules and beverages containing various concentrations and combinations of THC, CBG and CBN. The Alongside Canadian commercialization, the Company plans to pursue international commercialization opportunities through finished-products exports and licensing partnerships. Supporting Treatment Optimization and the Evolution of Cannabinoid-Based Medicine Through the introduction of the QUIXTM-powered portfolio, Avicanna aims to provide patients and health care practitioners with additional options that may support individualized treatment approaches and reduce reliance on combustible cannabis product.

Complemented by patient support and health care practitioner oversight, the Company aims to support treatment optimization and responsible cannabinoid use. Aras Azadian, CEO of Avicanna, commented: “The commercialization of products powered by QUIXTM nanotechnology represents another important milestone in our strategy of translating Avicanna’s scientific platform and proprietary technologies into differentiated, evidence-based commercial products. We believe QUIXTM strengthens our ability to support treatment optimization and the continued evolution and integration of cannabinoid-based medicine into patient care, while creating additional opportunities to commercialize and scale Avicanna’s intellectual property.”

About Avicanna Inc Avicanna is a commercial-stage international biopharmaceutical company focused on the advancement and commercialization of cannabinoid-based products and formulations for the global medical and pharmaceutical market segments. Avicanna has an established scientific platform including R&D and clinical development leading to the commercialization of more than thirty proprietary, evidence-based finished products and supporting four commercial stage business pillars. - Medical Cannabis formulary (RHO PhytoTM): The formulary offers a diverse range of proprietary products including oral, sublingual, topical, and transdermal deliveries with varying ratios of cannabinoids, supported by ongoing patient and medical community education.

RHO Phyto is an established brand in Canada currently available nationwide across several channels and expanding into new international markets. - Medical cannabis care platform (MyMedi.ca): MyMedi.ca is a medical cannabis care platform formed with the aim to better serve medical cannabis patients’ needs and enhance the medical cannabis patients’ journey. MyMedi.ca is operated by Northern Green Canada Inc. and features a diverse portfolio of products and bilingual pharmacist-led patient support programs.

MyMedi.ca also provides specialty services to distinct patient groups such as veterans and collaborates with public and private payers for adjudication and reimbursement. MyMedi.ca provides educational resources to the medical community to facilitate the incorporation of medical cannabis into health care regimens. - Pharmaceutical pipeline: Leveraging Avicanna’s scientific platform, vertical integration, and real-world evidence, Avicanna has developed a pipeline of proprietary, indication-specific cannabinoid-based candidates that are in various stages of clinical development.

These cannabinoid-based candidates aim to address unmet needs in the areas of dermatology, chronic pain, and various neurological disorders. - Active pharmaceutical ingredients (Aureus Santa MartaTM): Active pharmaceutical ingredients supplied by the Company’s majority owned subsidiary Santa Marta Golden Hemp SAS (“SMGH”) is a commercial-stage business dedicated to providing various forms of high-quality CBD, THC and CBG to the Company’s international partners for use in the development and production of food, cosmetics, medical, and pharmaceutical products. SMGH also forms part of the Company’s supply chain and is a